Efficacy and tolerability of low molecular weight hyaluronic acid sodium salt 0.2% cream in rosacea

Journal of Drugs in Dermatology

Volumn 12, Issue 6, 2013, Pages 664-667

  Schlesinger, Todd E ^a   Powell, Callie Rowland ^a  

^a Dermatology and Laser Center of Charleston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID;

ADULT; AGED; APPLICATION SITE BURNING; APPLICATION SITE DRYNESS; ARTICLE; CLINICAL ARTICLE; CREAM; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FACE ERYTHEMA; HUMAN; MOLECULAR WEIGHT; PAPULE; ROSACEA; SKIN MANIFESTATION; TELANGIECTASIA; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; HYALURONIC ACID; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOLECULAR WEIGHT; PROSPECTIVE STUDIES; ROSACEA; TIME FACTORS; YOUNG ADULT;

EID: 84878667421     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Wilkin JK. Rosacea: pathophysiology and treatment. Arch Dermatol. 1994;130(3):359-362. (Pubitemid 24107876)
2. Bechtel M, Bechtel A. Rosacea: Choosing Among the Topical and Systemic Therapeutic options. Practical Dermatology. 2011;8(12):45-48.
3. Lee J, Jung J, Bang D. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease. Journal Of The European Academy Of Dermatology And Venereology: JEADV. May 2008;22(5):590-595. (Pubitemid 351541055)
4. Gariboldi S, Palazzo M, Zanobbio L, et al. Low molecular weight hyaluronic acid increases the self- defense of skin epithelium by induction of β-defensin 2 via TLR2 and TLR4. J Immunol. 2008;181(3):2103-2110.
5. Price R, Myers S, Leigh I, Navsaria H. The Role of Hyaluronic Acid in Wound Healing: Assessment of Clinical Evidence. American Journal of Clinical Dermatology. December 2005;6(6):393-402. (Pubitemid 43128291)
6. Thiboutot D, Thieroff-Ekerdt R, Graupe, K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-45. (Pubitemid 36706214)
7. Bamford JT, Elliott B, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50:107-8. (Pubitemid 38095664)
8. Passi S. Pharmacology and pharmacokinetics of azelaic acid. Rev Contemp Pharmacother. 1993;4:441-7.
9. Bojar RA, Holland KT. Azelaic acid: a review of its antimicrobial properties. Rev Contemp Pharmacother. 1993;4:403-14.
10. Narayanan S; Hünerbein A; Getie M, et al. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007;59(8):1125-30. (Pubitemid 47265360)
11. Del Rosso JQ, Gallo RL, Kircik L, et al. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic collelations of abnormal innate immune response in rosacea-prone skin. J Drugs Dermatol. 2012;11(6):694-700.
12. Steinhoff M, Buddenkotte J, Aubetr J, et al. Clinical, cellular and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol. 2011;15:2-11.
13. Kanda, N, Watanabe S. Histamine enhances the production of human β-defensin-2 in human keratinocytes. Am J Physiol. 2007;293:C1916-C1923. (Pubitemid 350255069)
14. Braff, MH, Gallo RL. Antimicrobial peptides: an essential component of the skin defensive barrier. Curr Top Microbiol Immnunol. 2006;306:91-110. (Pubitemid 47400319)
15. Donnarumma G, Paoletti I, Buommino E, et al. Malassezia furfur induces the expression of β-defensin-2 inhuman keratinocytes in a protein kinase C-dependent manner. Arch Dermatol Res. 2004;295: 474-481. (Pubitemid 38543971)
16. Jiang D, Liang J, Noble PW. Hyaluronan in tissue and repair. Annu Rev Cell Dev Biol. 2007;23:435-461.